VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance

BACKGROUND: Glioblastoma ranks among the most lethal cancers, with current therapies offering only palliation. Paracrine vascular endothelial growth factor (VEGF) signaling has been targeted using anti-angiogenic agents, whereas autocrine VEGF/VEGF receptor 2 (VEGFR2) signaling is poorly understood....

Descripción completa

Detalles Bibliográficos
Autores principales: Michaelsen, Signe R, Staberg, Mikkel, Pedersen, Henriette, Jensen, Kamilla E, Majewski, Wiktor, Broholm, Helle, Nedergaard, Mette K, Meulengracht, Christopher, Urup, Thomas, Villingshøj, Mette, Lukacova, Slávka, Skjøth-Rasmussen, Jane, Brennum, Jannick, Kjær, Andreas, Lassen, Ulrik, Stockhausen, Marie-Thérése, Poulsen, Hans S, Hamerlik, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176801/
https://www.ncbi.nlm.nih.gov/pubmed/29939339
http://dx.doi.org/10.1093/neuonc/noy103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176801/
https://www.ncbi.nlm.nih.gov/pubmed/29939339
http://dx.doi.org/10.1093/neuonc/noy103

Ejemplares similares